

Stem Cell Therapy International, Inc.  
Form 8-K  
December 01, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 1, 2009

**STEM CELL THERAPY INTERNATIONAL, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Nevada  
(State or other jurisdiction of  
incorporation or organization)

000-51931  
(Commission  
File Number)

88-0374180  
(I.R.S. Employer  
Identification No.)

Edgar Filing: Stem Cell Therapy International, Inc. - Form 8-K

**13406 Racetrack Road #233, Tampa, FL 33626**

**(Address of principal executive offices zip code)**

**(813) 283-2556**

**(Registrant's telephone number, including area code)**

**(former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

**ITEM 7.01 REGULATION FD DISCLOSURE**

Stem Cell Therapy International Inc. (SCII, or the Company ), announced today that it has signed an agreement with Histostem Ltd. of South Korea ( Histostem ), for the exclusive, worldwide rights to the distribution of the Company s existing SteMixx line of stem cell based cosmetic products, as well as future products under development. A copy of the release is attached as Exhibit 99.1.

The information furnished herein, including Exhibit 99.1, is not deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

*Exhibits*

99.1 Press release dated December 1, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEM CELL THERAPY INTERNATIONAL, INC.

By: /s/ ANDREW J. NORSTRUD  
Name: **Andrew J. Norstrud**  
Title: **Chief Financial Officer**

Date: December 1, 2009